Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial
Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterfer...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Artículo |
| Lenguaje: | inglés |
| Publicado: |
2003
|
| Materias: | |
| Acceso en línea: | http://eprints.uanl.mx/23487/1/23487.pdf |
| _version_ | 1838551004994338816 |
|---|---|
| author | Bosques Padilla, Francisco Javier Trejo Estrada, Rafael Campollo Rivas, Octaivio Cortez Hernández, Carlos Alejandro Dehesa Violante, Margarita Maldonado Garza, Héctor Jesús Pérez Gómez, Raúl Cabrera Valdespino, Armando |
| author_facet | Bosques Padilla, Francisco Javier Trejo Estrada, Rafael Campollo Rivas, Octaivio Cortez Hernández, Carlos Alejandro Dehesa Violante, Margarita Maldonado Garza, Héctor Jesús Pérez Gómez, Raúl Cabrera Valdespino, Armando |
| author_sort | Bosques Padilla, Francisco Javier |
| collection | Repositorio Institucional |
| description | Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus rib-avirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Thirty-two patients were randomly assigned to treatment, and received at least one dose of medication consisting of 180 μ of peginterferon alfa-2a once weekly plus daily ribavirin (1,000 or 1,200 mg, depending on body weight) (n = 14), weekly peginterferon alfa-2a plus daily placebo (n = 6), or three million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks (n = 12). More patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than patients who received interferon alfa-2b plus ribavirin (7/14 vs. 4/12) or peginterferon alfa-2a plus placebo (0/6). The overall safety profiles of the three treatment regimens were similar. In conclusion, for patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained viral reduction compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone. |
| format | Article |
| id | eprints-23487 |
| institution | UANL |
| language | English |
| publishDate | 2003 |
| record_format | eprints |
| spelling | eprints-234872025-07-23T15:50:07Z http://eprints.uanl.mx/23487/ Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial Bosques Padilla, Francisco Javier Trejo Estrada, Rafael Campollo Rivas, Octaivio Cortez Hernández, Carlos Alejandro Dehesa Violante, Margarita Maldonado Garza, Héctor Jesús Pérez Gómez, Raúl Cabrera Valdespino, Armando RC Medicina Interna, Psiquiatría, Neurología Treatment with polyethylene glycol-modified interferon alfa-2a (peginterferon) alone produces significantly higher sustained antiviral responses than treatment with interferon alfa-2a alone in patients with chronic hepatitis C virus (HCV) infection. We compared the efficacy and safety of peginterferon alfa-2a plus rib-avirin, interferon alfa-2b plus ribavirin, and peginterferon alfa-2a alone in the initial treatment of chronic hepatitis C. Thirty-two patients were randomly assigned to treatment, and received at least one dose of medication consisting of 180 μ of peginterferon alfa-2a once weekly plus daily ribavirin (1,000 or 1,200 mg, depending on body weight) (n = 14), weekly peginterferon alfa-2a plus daily placebo (n = 6), or three million units of interferon alfa-2b thrice weekly plus daily ribavirin for 48 weeks (n = 12). More patients who received peginterferon alfa-2a plus ribavirin had a sustained virologic response (defined as the absence of detectable HCV RNA 24 weeks after cessation of therapy) than patients who received interferon alfa-2b plus ribavirin (7/14 vs. 4/12) or peginterferon alfa-2a plus placebo (0/6). The overall safety profiles of the three treatment regimens were similar. In conclusion, for patients with chronic hepatitis C, once-weekly peginterferon alfa-2a plus ribavirin was tolerated as well as interferon alfa-2b plus ribavirin and produced significant improvements in the rate of sustained viral reduction compared with interferon alfa-2b plus ribavirin or peginterferon alfa-2a alone. 2003 Article PeerReviewed text en cc_by_nc_nd http://eprints.uanl.mx/23487/1/23487.pdf http://eprints.uanl.mx/23487/1.haspreviewThumbnailVersion/23487.pdf Bosques Padilla, Francisco Javier y Trejo Estrada, Rafael y Campollo Rivas, Octaivio y Cortez Hernández, Carlos Alejandro y Dehesa Violante, Margarita y Maldonado Garza, Héctor Jesús y Pérez Gómez, Raúl y Cabrera Valdespino, Armando (2003) Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial. Annals of hepatology, 2 (3). pp. 135-139. ISSN 1665-2681 http://doi.org/10.1016/S1665-2681(19)32139-8 doi:10.1016/S1665-2681(19)32139-8 |
| spellingShingle | RC Medicina Interna, Psiquiatría, Neurología Bosques Padilla, Francisco Javier Trejo Estrada, Rafael Campollo Rivas, Octaivio Cortez Hernández, Carlos Alejandro Dehesa Violante, Margarita Maldonado Garza, Héctor Jesús Pérez Gómez, Raúl Cabrera Valdespino, Armando Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
| thumbnail | https://rediab.uanl.mx/themes/sandal5/images/online.png |
| title | Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
| title_full | Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
| title_fullStr | Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
| title_full_unstemmed | Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
| title_short | Peginterferon alfa-2a plus ribavirin for treating chronic hepatitis C virus infection: Analysis of Mexican patients included in a multicenter international clinical trial |
| title_sort | peginterferon alfa 2a plus ribavirin for treating chronic hepatitis c virus infection analysis of mexican patients included in a multicenter international clinical trial |
| topic | RC Medicina Interna, Psiquiatría, Neurología |
| url | http://eprints.uanl.mx/23487/1/23487.pdf |
| work_keys_str_mv | AT bosquespadillafranciscojavier peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT trejoestradarafael peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT campollorivasoctaivio peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT cortezhernandezcarlosalejandro peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT dehesaviolantemargarita peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT maldonadogarzahectorjesus peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT perezgomezraul peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial AT cabreravaldespinoarmando peginterferonalfa2aplusribavirinfortreatingchronichepatitiscvirusinfectionanalysisofmexicanpatientsincludedinamulticenterinternationalclinicaltrial |